Product Description
Cyclobenzaprine is used with rest, physical therapy, and other measures to relax muscles and relieve pain and discomfort caused by strains, sprains, and other muscle injuries. Cyclobenzaprine is in a class of medications called skeletal muscle relaxants. It works by acting in the brain and nervous system to allow the muscles to relax. (Sourced from: https://medlineplus.gov/druginfo/meds/a682514.html)
Mechanisms of Action: 5-HT2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Sublingual
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Bangladesh | Brazil | Canada | Chile | Colombia | Dominican Republic | Ecuador | Egypt | India | Italy | Jordan | Korea | Lebanon | Malta | Mexico | Pakistan | Peru | Portugal | Russia | Saudi Arabia | South Africa | Spain | Taiwan | Turkey | Ukraine | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Tonix Pharmaceuticals
Company Location: CHATHAM NJ 07928
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Fibromyalgia|Myofascial Pain Syndromes
Phase 2: Communicable Diseases|Fractures, Stress|Post Acute COVID-19 Syndrome|Stress Disorders, Post-Traumatic|Stress Disorders, Traumatic, Acute
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| OASIS | P2 |
Not yet recruiting |
Stress Disorders, Post-Traumatic|Stress Disorders, Traumatic, Acute|Fractures, Stress |
2025-09-01 |
|
| RESILIENT | P3 |
Completed |
Fibromyalgia|Myofascial Pain Syndromes |
2023-11-14 |
86% |
| PREVAIL | P2 |
Completed |
Post Acute COVID-19 Syndrome|Communicable Diseases |
2023-07-12 |